FDA approves Cardiovascular Systems' catheter trial
This article was originally published in Clinica
Executive Summary
Cardiovascular Systems has received a conditional Investigational Device Exemption (IDE) approval from the US FDA to begin a trial of its Diamondback 360° catheter. The catheter, cleared by the FDA in 2007 for the treatment of peripheral arterial disease, will now be tested in the treatment of calcified coronary lesions. A pivotal trial, ORBIT II, will initially enrol up to 100 patients. St Paul, Minnesota-based Cardiovascular Systems estimates the US market for coronary interventions at more than $4bn.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?